{
  "denotations": [
    {
      "id": "T1",
      "obj": "Disease",
      "span": {
        "begin": 32,
        "end": 38
      }
    },
    {
      "id": "T2",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 92,
        "end": 98
      }
    },
    {
      "id": "T4",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 137,
        "end": 143
      }
    },
    {
      "id": "T6",
      "obj": "Chemical",
      "span": {
        "begin": 187,
        "end": 197
      }
    },
    {
      "id": "T7",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 216,
        "end": 222
      }
    },
    {
      "id": "T12",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 59,
        "end": 62
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 102,
        "end": 105
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "26791794_9",
  "text": "One patient each whose advanced tumors harbored high level MET amplification with wild-type PIK3CA or MET exon 14 skipping mutation with PIK3CA - p.Glu542Lys had significant responses to crizotinib ; suggesting that PIK3CA co-mutation did not affect clinical response ."
}
